Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.63 |
| ▸ | CA4 | P22748 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA6 | P23280 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583041 | 1.00 | CA2 (0.63) | CA2CA4LMNACA12CA1 | |
| SCHEMBL13545443 | 0.86 | CA2 (0.61) | CA2CA4LMNACA12CA1 | |
| SCHEMBL3585070 | 0.81 | CA2 (0.47) | CA2CA4LMNACA12CA1 | |
| SCHEMBL3586845 | 0.81 | CA2 (0.47) | CA2CA4LMNACA12CA1 | |
| SCHEMBL3577810 | 0.81 | CA2 (0.47) | CA2CA4LMNACA12CA1 | |
| SCHEMBL19826556 | 0.81 | CA2 (0.73) | CA2CA4LMNACA12CA1 | |
| SCHEMBL18651229 | 0.81 | CA2 (0.45) | CA2CA4LMNACA12CA1 | |
| SCHEMBL12603505 | 0.81 | CA2 (0.75) | CA2CA4LMNACA12CA1 | |
| SCHEMBL13064108 | 0.81 | CA2 (0.72) | CA2CA4LMNACA12CA1 | |
| SCHEMBL14040597 | 0.79 | CA2 (0.69) | CA2CA4LMNACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396193-A | Method for preparing alpha-sulfonamido acetals from fatty aldehydes and sulfonamides | 西北工业大学 | 2023-07-07 | — | — | CN | claimed |
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | USV LTD. (IN) | 2010-01-14 | — | — | US | claimed |
| EP-2079749-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (R)-(+)-4-(ETHYIAMINO)-3,4-DIHYDRO-2-(3- METHOXYPROPYL)-2H-THIENO[3,2-E]-L,2-THIAZINE-6-SULFONAMIDE-L,L-DIOXIDE | USV LIMITED (IN) | 2009-07-22 | — | — | EP | claimed |
| WO-2008062463-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (R)-(+)-4-(ETHYIAMINO)-3,4-DIHYDRO-2-(3- METHOXYPROPYL)-2H-THIENO[3,2-E]-L,2-THIAZINE-6-SULFONAMIDE-L,L-DIOXIDE | USV LIMITED (IN) | 2008-05-29 | — | — | WO | claimed |
| CN-116396193-A | Method for preparing alpha-sulfonamido acetals from fatty aldehydes and sulfonamides | 西北工业大学 | 2023-07-07 | — | — | CN | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | Graybug Vision, Inc. (US) | 2017-03-23 | — | — | US | disclosed |
| US-8344136-B2 | Process for the preparation of brinzolamide | PHF S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | USV LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | USV LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | USV LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| WO-2008132114-A1 | PROCESS FOR THE PREPARATION OF BRINZOLAMIDE AND INTERMEDIATES THEREOF | DUKE CHEM, S. A. (ES) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132114-A1 | PROCESS FOR THE PREPARATION OF BRINZOLAMIDE AND INTERMEDIATES THEREOF | DUKE CHEM, S. A. (ES) | 2008-11-06 | — | — | WO | disclosed |
| EP-1985618-A1 | Process for the preparation of brinzolamide and intermediates thereof | Duke Chem, S. A. (ES) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | PTGIR, PTGIS, CA2 | CA2 3/4885CA4 38/4885LMNA 1688/4885 |
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | SULT1E1, SULT1A1, SULT2A1 | CA2 1631/4885CA4 709/4885LMNA 2986/4885 |
| US-20180064823-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | CA2 3/4885CA4 38/4885LMNA 1688/4885 |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | CA2 3/4885CA4 38/4885LMNA 1688/4885 |
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | CA2 3/4885CA4 38/4885LMNA 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.